权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Gulf South IPF Clinical Research Network

南海湾 IPF 临床研究网络

基本信息

批准号：
7616471
负责人：
Joseph A Lasky
金额：
$ 15.92万
依托单位：
TULANE UNIVERSITY OF LOUISIANA
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-05-01 至 2011-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7616471
关键词：
Acetylcysteine Adrenal Cortex Hormones Adverse effects Anti-Inflammatory Agents Anti-inflammatory Antioxidants Attention Azathioprine Basic Science Bladder Bone Marrow CCL2 gene Cessation of life Chemotactic Factors Cicatrix Clinic Clinical Clinical Research Clinical Trials Colchicine Controlled Study Cyclophosphamide Data Deterioration Diabetes Mellitus Diagnosis Dinoprostone Disease Disease Progression Dyspnea Effectiveness Emotional Disturbance Endothelin Enrollment Epidemiologic Studies Europe Evidence Based Medicine Expert Opinion Fibrosis Foundations Glucose Intolerance Glutathione Goals Hamman-Rich syndrome Imatinib mesylate Immunosuppressive Agents Incidence Infection Inflammatory Interferon Type II Interleukin-1 Knowledge Laboratories Leukotrienes Liver Lung Lung Transplantation Mission Myopathy Newly Diagnosed Oncogenic Organ Pathogenesis Pathway interactions Patients Pharmaceutical Preparations Platelet-Derived Growth Factor Predisposition Prevalence Prostaglandins Pulmonary Fibrosis Randomized Randomized Controlled Trials Reporting Research Research Personnel Signal Transduction Steroids Testing Time Transforming Growth Factor beta Transplantation Treatment Protocols Tumor Necrosis Factor-alpha United States United States National Institutes of Health Up-Regulation Urokinase Weight Gain abstracting antioxidant therapy base demographics disability drug efficacy effective therapy efficacy testing evidence base experience human TNF protein inhibitor/antagonist mortality novel strategies prevent prospective pulmonary function

项目摘要

DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a debilitating and fatal disease for which there is no known cure. Recent epidemiologic studies have discerned that IPF is more common than previously recognized with an estimated 30,000 newly diagnosed cases in the United States yearly. There have been numerous expert reviews of late that have called our attention to the lack of evidence regarding the effectiveness of previously recommended treatment regimens that rely solely on the use of corticosteroids with or without other immunosuppressants for the treatment of IPF. It is now time to test the efficacy of novel approaches derived from decades of support from the NIH, ALA and private foundations for clinical and basic science lung fibrosis research. The overall goal of this proposal is to test the hypothesis that the most effective therapy for preventing disease progression will require multiple agents and is based on the knowledge that multiple profibrotic pathways are activated, and many antifibrotic pathways are disrupted in the lungs of patients with IPF. This application includes two proposals supported by promising preliminary data from the laboratories of the investigators and others, which involve anti-oxidant therapy using N-acetylcysteine (NAC) in combination with either imatinib mesylate (an inhibitor of platelet-derived growth factor and transforming growth factor beta signal transduction) or urokinase (a potent fibrinolytic). The investigators for this proposal have clearly demonstrated that they are capable of enrolling the number of patients required to support the proposed research mission of establishing an effective clinical IPF research network, through their past and current involvement in multi-center IPF clinical trials, as well as their establishment and conduct of an ongoing investigator-initiated IPF trial. The Gulf South Clinical Research Network combines the positive attributes of the investigators' experience in basic science and clinical lung fibrosis research with the ability to provide access to clinical IPF trials to the unique demographics of the Gulf South. (End of Abstract)

描述（由申请人提供）：特发性肺纤维化（IPF）是一种使人衰弱的致命性疾病，目前尚无治愈方法。最近的流行病学研究发现，IPF比以前认识到的更常见，在美国每年估计有30，000例新诊断病例。最近有许多专家审查，提醒我们注意缺乏关于先前推荐的治疗方案有效性的证据，这些治疗方案仅依赖于使用皮质类固醇联合或不联合其他免疫抑制剂治疗IPF。现在是时候测试新方法的有效性了，这些方法来自NIH，ALA和私人基金会对临床和基础科学肺纤维化研究的数十年支持。本提案的总体目标是检验以下假设：预防疾病进展的最有效治疗需要多种药物，并且基于IPF患者肺部多种促纤维化途径被激活和许多抗纤维化途径被破坏的知识。该申请包括两项提案，这些提案得到了研究者和其他人实验室的有希望的初步数据的支持，其中涉及使用N-乙酰半胱氨酸（NAC）与甲磺酸伊马替尼（血小板衍生生长因子和转化生长因子β信号转导的抑制剂）或尿激酶（一种有效的纤维蛋白溶解剂）组合的抗氧化治疗。本提案的研究者已明确证明，通过他们过去和现在参与的多中心IPF临床试验，以及他们建立和开展的正在进行的由研究者发起的IPF试验，他们能够招募支持建立有效的IPF临床研究网络的拟定研究使命所需的患者数量。海湾南部临床研究网络将研究者在基础科学和临床肺纤维化研究方面的经验的积极属性与向海湾南部独特的人口统计学提供临床IPF试验的能力相结合。 (End摘要）